- Report
- October 2024
- 189 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 363 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- September 2024
- 84 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- September 2024
- 255 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- June 2024
- 80 Pages
United States
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2023
- 197 Pages
Global
From €4879EUR$5,292USD£3,950GBP
- Report
- April 2023
- 90 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- March 2020
- 136 Pages
Global
From €4247EUR$4,450USD£3,558GBP
- Report
- January 2024
- 200 Pages
Global
From €3961EUR$4,150USD£3,318GBP
- Report
- April 2023
- 175 Pages
Global
€4576EUR$4,795USD£3,834GBP
- Report
- October 2021
- 103 Pages
United States
From €2625EUR$2,750USD£2,199GBP
€5249EUR$5,500USD£4,398GBP
- Report
- May 2022
- 71 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Book
- June 2016
- 360 Pages
- Book
- January 2011
- 350 Pages

Anthrax is a biological agent used in biodefense. It is a highly infectious disease caused by the bacterium Bacillus anthracis. Anthrax is a potential weapon of bioterrorism and can be used to cause mass casualties. It is also used in the development of vaccines and treatments for biodefense.
The anthrax market is a rapidly growing sector of the biodefense industry. It is driven by the need for effective vaccines and treatments to protect against the threat of bioterrorism. Companies in the market are developing new technologies and products to address the threat of anthrax. These include vaccines, treatments, diagnostics, and detection systems.
Some companies in the anthrax market include Emergent BioSolutions, CSL Limited, Bavarian Nordic, and GlaxoSmithKline. Show Less Read more